Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): Final study results from the European IRISS registry study

被引：0
|
作者：
Khoramnia, Ramin [1 ]
Peto, Tunde [2 ]
Taylor, Simon R. [3 ]
Castro De Sousa, Joao Paulo [4 ]
Hill, Lauren
Bailey, Clare [5 ]
Chakravarthy, Usha [6 ]
机构：
[1] Heidelberg Univ, Dept Ophthalmol, Heidelberg, Baden Wurttembe, Germany
[2] Sch Med Dent & Biomed Sci, Ctr Publ Hlth, Belfast, North Ireland
[3] Univ Surrey, Dept Ophthalmol, Surrey, England
[4] Leiria Hosp Ctr, Ophthalmol Dept, Leiria, Portugal
[5] Bristol Eye Hosp, Bristol, England
[6] Queens Univ Belfast, Ctr Publ Hlth, Belfast, North Ireland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2022年 / 63卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
2182 - F0
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Two-year interim safety results of the 0.2 μg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
    Mansour, Sam E.
    Kiernan, Daniel F.
    Roth, Daniel B.
    Eichenbaum, David
    Holekamp, Nancy M.
    Kaba, Samer
    Werts, Erica
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2021, 105 (03) : 414 - 419
  • [22] Evaluation of the clinical effectiveness of fluocinolone acetonide 190 μg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes
    Currie, Craig J.
    Holden, Sarah E.
    Berni, Ellen
    Owens, David R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 : 19 - 31
  • [23] The use of intravitreal implant ILUVIEN ® (fluocinolone acetonide) after prior OZURDEX ® Implant (DEX) (Dexamathason) in patients with diabetic macular edema (DME) - Efficacy and safety outcomes from the University Eye Clinic in Frankfurt, Germany
    Singh, Pankaj
    Chedid, Adonis
    Deuchler, Svenja
    Kohnen, Thomas
    Mueller, Michael
    Koch, Frank H. J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [24] Efficacy and safety of corticosteroid implant (Fluocinolone Acetonide (FAc) 0.2 lg/day, Iluvien ®) for management of Diabetic Macular Edema (DME): a real-life study
    Vieira, M.
    Pereira, J.
    Santos, M.
    Arruda, H.
    Sousa, J.
    ACTA OPHTHALMOLOGICA, 2018, 96 : 135 - 136
  • [25] Reduced vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (FAc, ILUVIEN) implant in patients with persistent or recurrent DME - results from the ILUVIT study
    Deuchler, Svenja
    Singh, Pankaj
    Chedid, Adonis
    Brui, Natallia
    Kohnen, Thomas
    Ackermann, Hanns
    Koch, Frank H. J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [26] Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study
    Deuchler, Svenja K.
    Schubert, Ralf
    Singh, Pankaj
    Chedid, Adonis
    Kenikstul, Ninel
    Scott, Julia
    Kohnen, Thomas
    Ackermann, Hanns
    Koch, Frank
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 260 (08) : 2537 - 2547
  • [27] Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema The PALADIN Study
    Singer, Michael A.
    Sheth, Veeral
    Mansour, Sam E.
    Coughlin, Brandon
    Gonzalez, Victor H.
    OPHTHALMOLOGY, 2022, 129 (06) : 605 - 613
  • [28] Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)—results from the ILUVIT study
    Svenja K. Deuchler
    Ralf Schubert
    Pankaj Singh
    Adonis Chedid
    Ninel Kenikstul
    Julia Scott
    Thomas Kohnen
    Hanns Ackermann
    Frank Koch
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 2537 - 2547
  • [29] Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study
    José María Ruiz-Moreno
    Alfredo Adán
    María Lafuente
    Mónica Asencio Durán
    Luís Arias Barquet
    Alfredo García Layana
    Javier Araiz Iribarren
    International Ophthalmology, 2023, 43 : 4639 - 4649
  • [30] Efficacy and Safety of Intravitreal Fluocinolone Acetonide Implant for Chronic Diabetic Macular Edema Previously Treated in Real-Life Practice: The REALFAc Study
    Mathis, Thibaud
    Papegaey, Maxence
    Ricard, Cecile
    Rezkallah, Amina
    Matonti, Frederic
    Sudhalkar, Aditya
    Vartin, Cristina
    Dot, Corinne
    Kodjikian, Laurent
    PHARMACEUTICS, 2022, 14 (04)
12345